KALA - KALA BIO, Inc.
Previous close
6.14
0.250 4.072%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:11:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$5.89
0.25
4.24%
Fundamental analysis
22%
Profitability
18%
Dept financing
21%
Liquidity
73%
Performance
15%
Performance
5 Days
5.41%
1 Month
-9.70%
3 Months
14.29%
6 Months
33.33%
1 Year
-15.33%
2 Year
59.18%
Key data
Stock price
$6.14
DAY RANGE
$5.89 - $6.11
52 WEEK RANGE
$4.79 - $9.25
52 WEEK CHANGE
-$18.96
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Mark T. Iwicki
Region: US
Website: kalarx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kalarx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.
Recent news